(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30398 A2

(51) International Patent Classification[7]: A61K 9/16, 9/50, 9/22

(21) International Application Number: PCT/GB01/04423

(22) International Filing Date: 4 October 2001 (04.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0025208.0 13 October 2000 (13.10.2000) GB

(71) Applicant *(for all designated States except US)*: **EUROCELTIQUE S.A.** [LU/LU]; 122, Boulevard de la Petrusse, Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PRATER, Derek, Allan** [GB/GB]; 28 Pearson Close, Milton, Cambridgeshire CB4 6YS (GB). **HASSAN, Mohammed** [GB/GB]; Harwood House, Oak Lane, Littleport, Cambridgeshire CB6 1RS (GB). **BLAND, Christopher, Robert** [GB/GB]; 15 Wichling Close, Canterbury, Kent CT2 7QR (GB).


(74) Agent: **RUFFLES, Graham, Keith**; Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: DELAYED RELEASE PHARMACEUTICAL FORMULATIONS



(57) Abstract: Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.

WO 02/30398 A2

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.